Gold Innovations Blog

Nanosphere, the nanotechnology-based healthcare company, has just released this press release announcing it has received 501(k) clearance from the US Food & Drug Administration for its influenza A & B and Respiratory Syncytial Virus (RSV) test and the Verigene SP System, with complete sample-to-result automation. This is an important milestone, as it allows patients access to the patented gold nanoparticle-based technology for influenza diagnosis in time for the coming flu season.

In a second piece of positive news for the company, a study has shown that the company’s gold-based technology has detected a protein specific to prostate cancer in 86 percent of blood samples compared with 25 percent for conventional tests. This data has been published in the Proceedings of the National Academy of Sciences, and has received widespread media coverage (for example see here for a thorough Bloomberg article).